FOI release

Reverse-transcription and residual-plasmid-DNA evidence in licensed mRNA products (2021-2024)

Some or all of the information requested was not provided because we determined that the cost to do so would exceed the appropriate limit.

Case reference FOI2026/00551

Received 18 May 2026

Published 21 July 2026

Request

See attached

Response

See attached

Documents

• FOI2026_00551(redacted).pdf (1.2 MB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.